Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
about
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerAt the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of boneCIViC databaseEpidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of gliomaEpidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaChallenges in EGFRvIII detection in head and neck squamous cell carcinoma.Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neckEGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.Membrane-Tethered Intracellular Domain of Amphiregulin Promotes Keratinocyte Proliferation.The EGF receptor ligand amphiregulin controls cell division via FoxM1Cetuximab: its unique place in head and neck cancer treatmentExpression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma.Head and neck cancer: from anatomy to biology.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceNovel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.Current Role of Dacomitinib in Head and Neck Cancer.A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.Prognostic and predictive value of EGFR in head and neck squamous cell carcinomaRandomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers.Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma.Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment.Biologic therapy in head and neck cancer: a road with hurdles.Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis.HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status.Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische OnkoComparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.EGFRwt/vIII-PKM2-β-catenin cascade affects proliferation and chemo-sensitivity in head and neck squamous cell carcinoma.
P2860
Q26852215-9966031E-5158-4747-8A6B-438351F17A30Q26866067-5570879F-A806-49A6-B13F-A0C6AA7109E9Q27612411-0854D9A6-AEBB-4DAE-B569-D53BBBB95629Q27853131-FE63B8F5-9ED2-4F12-A366-EFAE215079CFQ33734403-A471EF4B-6A73-405D-BB60-A2DF9AA95E8FQ33779199-114A6BCB-AEC9-4DE2-AA46-DFB7CDBF0EEAQ34181954-C5CE2D6B-2CBD-44C6-9FCD-6128832128F9Q35058799-64CAB459-5718-4BB9-BFAF-B5CCCBCB7927Q35640310-7C5D5E0A-A109-4FF7-B634-634DD4348FB0Q36302347-06D822E0-E637-4367-943C-E42CD88E8040Q36677686-93F1ACAC-E9CE-4C39-BB75-5D13C9B72FBDQ36678172-AE0CF49E-B945-4295-8114-2518AEE1706BQ36880604-0E3C43E8-558E-46B5-B3C4-5183F6EB6102Q37080154-2B162AD2-C137-4462-9EF6-4C2FE852C86FQ38082457-333E6A3C-158E-4078-B7A6-6308F25FEF5AQ38118934-D1E862AE-1CBB-4FF4-9825-BE104CE2359FQ38221292-45D7B6CC-78E0-48BB-9DD2-3FF60D1E5775Q38607113-77B08838-36D2-4B60-B0E9-E9950CBD5A78Q38806115-D74D58FD-DCC3-4812-B5D6-A3C5E77D869BQ38877945-AC7DD906-068C-4A8C-B396-B9888BD4A6A2Q38935842-207160F2-4D84-443E-AE3C-C857BA13D07BQ39187965-8144B4CB-03F2-4DEC-B6C9-1C41B51D16D4Q39366909-187DF949-5CE0-4DA4-B9F4-7ABE482CAA3FQ39375702-8AE948CD-E4E7-4046-A8CF-8708B45C8D77Q39423669-D3A7A1E5-BE46-4A1A-B016-ABA59C2B8B15Q39745151-F118AF5A-760A-42C0-82B2-DBF1A37258AAQ41605972-6C21B30E-CD32-45AF-8A25-8D69C02DB89FQ42085614-68D8E6CB-CF68-4186-8079-99983522AEE1Q42147221-13241C59-D78A-4304-B51E-99DE24567EACQ42213295-B62CFC97-3ABF-4BBC-998A-C143D75C8DAAQ42278129-6C81E750-6613-4520-9042-3BC6C81950D6Q43631346-0D3574D3-D95E-4A59-BEC6-0B5438C4CF94Q43979952-F7721286-CA11-49D1-8167-308122CC1544Q45346796-63E19DDC-B9D5-45BB-98BB-58ED5B75372AQ47283231-3B7E5ED9-44DE-477B-8A4D-5497D9B55BDAQ48546244-0F786683-29F0-4CFB-A2AE-33662E2CDA1F
P2860
Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@ast
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@en
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@nl
type
label
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@ast
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@en
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@nl
prefLabel
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@ast
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@en
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@nl
P2093
P3181
P1476
Expression of amphiregulin and ...... cetuximab-docetaxel treatment.
@en
P2093
Albrecht Stenzinger
Ingeborg Tinhofer
Konrad Klinghammer
Maren Knödler
Thomas Gauler
Ulrich Keilholz
Volker Budach
P304
P3181
P356
10.1158/1078-0432.CCR-10-3338
P407
P577
2011-08-01T00:00:00Z